A detailed history of Pro Share Advisors LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Pro Share Advisors LLC holds 18,742 shares of AVXL stock, worth $123,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,742
Previous 17,210 8.9%
Holding current value
$123,322
Previous $160,000 40.63%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$4.55 - $6.75 $6,970 - $10,341
1,532 Added 8.9%
18,742 $95,000
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $13,048 - $25,760
2,589 Added 17.71%
17,210 $160,000
Q3 2023

Nov 13, 2023

BUY
$6.55 - $9.37 $1,696 - $2,426
259 Added 1.8%
14,621 $95,000
Q2 2023

Aug 10, 2023

BUY
$7.66 - $9.5 $6,227 - $7,723
813 Added 6.0%
14,362 $116,000
Q1 2023

May 11, 2023

SELL
$8.32 - $11.75 $14,942 - $21,103
-1,796 Reduced 11.7%
13,549 $116,000
Q4 2022

Feb 02, 2023

BUY
$7.65 - $14.43 $8,912 - $16,810
1,165 Added 8.22%
15,345 $142,000
Q3 2022

Nov 04, 2022

BUY
$8.9 - $12.86 $4,325 - $6,249
486 Added 3.55%
14,180 $146,000
Q2 2022

Aug 01, 2022

SELL
$7.31 - $12.84 $49,466 - $86,888
-6,767 Reduced 33.07%
13,694 $136,000
Q1 2022

May 10, 2022

SELL
$9.74 - $17.69 $47,716 - $86,663
-4,899 Reduced 19.32%
20,461 $251,000
Q4 2021

Feb 08, 2022

BUY
$16.88 - $23.31 $428,076 - $591,141
25,360 New
25,360 $440,000
Q3 2021

Nov 12, 2021

SELL
$16.82 - $25.75 $270,802 - $414,575
-16,100 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$10.16 - $28.86 $4,724 - $13,419
465 Added 2.97%
16,100 $368,000
Q1 2021

May 14, 2021

BUY
$5.17 - $16.13 $20,711 - $64,616
4,006 Added 34.45%
15,635 $234,000
Q4 2020

Feb 09, 2021

BUY
$4.01 - $7.58 $46,632 - $88,147
11,629 New
11,629 $63,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $513M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.